

Name of the Issuer:	Global Health Limited	Last updated on	21-Nov-22
1 Type of Issue (IPO / FPO)	IPO		
<i>Source: Prospectus dated November 09, 2022</i>			
2 Issue Size (Rs. Million)*	22,055.70		
- Fresh Issue Size (Rs. Millions)	5,000.00		
- Offer for Sale Component (Rs. Millions)	17,055.70		
<i>*Source: Final post issue report dated November 17, 2022 and Prospectus dated November 09, 2022</i>			
3 Grade of issue along with name of the rating agency			
Name	Not Applicable		
Grade	Not Applicable		
<i>Source: Prospectus dated November 09, 2022</i>			
4 Subscription Level (Number of times)	7.11*		
<i>*Source: Final post issue report dated November 17, 2022</i>			
<i>*The above figure is after technical rejections and including Anchor Investors</i>			
5 QIB Holding (as a % of outstanding capital) as disclosed to stock exchanges			
Particulars	%		
(i) allotment in the issue ⁽¹⁾	14.54%		
(ii) at the end of 1st Quarter immediately after the listing (December 31, 2022)*	Not Available		
(iii) at the end of 1st FY (March 31, 2023)*	Not Available		
(iv) at the end of 2nd FY (March 31, 2024)*	Not Available		
(v) at the end of 3rd FY (March 31, 2025)*	Not Available		
<i>*QIB Holding not disclosed as reporting for the relevant period / fiscal year has not been completed.</i>			
<i>(1) Source: Reporting with the BSE. Represents holding of Institutions category</i>			

6 Financials of the issuer

Parameters	(In Rs. Millions)		
	1st FY (March 31, 2023)*	2nd FY (March 31, 2024)*	3rd FY (March 31, 2025)*
Income from Operations	Not Available	Not Available	Not Available
Net Profit for the period	Not Available	Not Available	Not Available
Paid-up equity share capital	Not Available	Not Available	Not Available
Reserves excluding revaluation reserves	Not Available	Not Available	Not Available

**Financials not disclosed as reporting for the relevant fiscal year has not been completed.*

7 Trading Status in the scrip of the issuer

Company's Equity Shares are listed on both BSE Limited and National Stock Exchange of India Limited
The Shares have not been suspended or delisted.

Particulars	Status
(i) at the end of 1st FY (March 31, 2023)*	Not Available
(ii) at the end of 2nd FY (March 31, 2024)*	Not Available
(iii) at the end of 3rd FY (March 31, 2025)*	Not Available

**Trading status not disclosed as the relevant fiscal year has not been completed.*

8 Change in Directors of issuer from the disclosures in the offer document

Particulars	Name of the Director	Appointed / Resigned
(i) at the end of 1st FY (March 31, 2023)*	Nil	Not Applicable
(ii) at the end of 2nd FY (March 31, 2024)*	Nil	Not Applicable
(iii) at the end of 3rd FY (March 31, 2025)*	Nil	Not Applicable

Source: Stock Exchange Filings

** Changes in Directors not disclosed as the relevant fiscal year has not been completed.*

9 Status of implementation of project/ commencement of commercial production

(i) as disclosed in the offer document	Not Applicable
(ii) Actual implementation	Not Applicable
(iii) Reasons for delay in implementation, if any	Not applicable

10 Status of utilization of issue proceeds

(i) as disclosed in the offer document

Utilization of the proceeds of the Fresh Issue

Particulars	Amount (in ₹ million)
Gross proceeds of the Fresh Issue	5,000.00
Less Issue related expenses	232.99
Net Proceeds	4,767.01

Utilisation of the Net Proceeds (in ₹ million)

Particulars	Total estimated amount/cost	Estimated Utilization of Net Proceeds in FY 2023
Investment in two of our Subsidiaries, GHPPL and MHPL, in the form of debt or equity for repayment / prepayment of borrowings, in full or part, of such Subsidiaries	3,750.00	3,750.00
General corporate purposes	1,017.10	1,017.10
Total	4,767.10	4,767.10

Source: Prospectus dated November 09, 2022

(ii) Actual utilization

Utilisation of the Net Proceeds

(in ₹ million)

Particulars	Amount to be deployed from Net Proceeds	Amount deployed/utilized as at September 30, 2022*	Amount unutilized as at September 30, 2022*
Investment in two of our Subsidiaries, GHPPL and MHPL, in the form of debt or equity for repayment / prepayment of borrowings, in full or part, of such Subsidiaries	3,750.00	Not Available	Not Available
General corporate purposes	1,017.10	Not Available	Not Available
Total	4,767.10	Not Available	Not Available

* Monitoring Agency Report is not available as the relevant period of disclosure has not been completed.

(iii) Reasons for deviation, if any Not applicable

11 Comments of monitoring agency

(a) Comments on use of funds	Not Available
(b) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document	
(c) Any other reservations expressed by the monitoring agency about the end use of funds	

Monitoring Agency Report is not available as the period of disclosure year has not been completed.

12 Pricing Data

Issue Price (Rs.): 336
 Designated Stock Exchange: NSE
 Listing Date: 16-Nov-22

Price parameters	At close of listing day (November 16, 2022)	At close of 30th calendar day from listing day (December 15, 2022) ⁽¹⁾	At close of 90th calendar day from listing day (February 15, 2023) ⁽²⁾	As at the end of 1st FY after the listing of the issue (March 31, 2023) ⁽³⁾⁽⁴⁾		
				Closing price	High (during the FY)	Low (during the FY)
Market Price on Designated Stock Exchange ⁽⁵⁾	415.30	Not Available	Not Available	Not Available	Not Available	Not Available
NIFTY 50 ⁽⁵⁾	18,409.65	Not Available	Not Available	Not Available	Not Available	Not Available
Sectoral Index ⁽⁶⁾	Not Applicable			Not Applicable		

Price parameters	As at the end of 2nd FY after the listing of the issue (March 31, 2024) ⁽³⁾⁽⁴⁾			As at the end of 3rd FY after the listing of the issue (March 31, 2025) ⁽³⁾⁽⁴⁾		
	Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)
Market Price on Designated Stock Exchange ⁽⁵⁾	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available
NIFTY 50 ⁽⁵⁾	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available
Sectoral Index ⁽⁶⁾	Not Applicable			Not Applicable		

Source: NSE website

Note:

- (1) 30th calendar day shall be taken as listing date plus 29 calendar days.
 (2) 90th calendar day shall be taken as listing date plus 89 calendar days.
 (3) High and Low based on intra day prices
 (4) Pricing data not disclosed as the relevant period/ fiscal year has not completed
 (5) In case of any reporting day falling on a holiday, previous trading day prices/values have been disclosed.
 (6) Comparable Sectoral index is not available

13 Basis for Issue Price

Accounting ratio	As disclosed in the offer document ⁽¹⁾	At the end of 1st FY (March 31, 2023) ⁽²⁾	At the end of 2nd FY (March 31, 2024) ⁽²⁾	At the end of 3rd FY (March 31, 2025) ⁽²⁾	
EPS	Issuer:				
	Consolidated (Basic)	7.78	Not Available	Not Available	
	Consolidated (Diluted)	7.77	Not Available	Not Available	
	Peer Group: (Consolidated)				
	Apollo Hospitals Enterprises Limited	73.42	Not Available	Not Available	
	Fortis Healthcare Limited	7.35	Not Available	Not Available	
	Max Healthcare Insitute Limited	6.24			
	Narayana Hrudayalaya Limited	16.84	Not Available	Not Available	
	Industry Avg:	25.96	N.A.	N.A.	N.A.
	Revenue from Operations (Rs. Million)	Issuer:			
Consolidated (Diluted)		22,058.17	Not Available	Not Available	
Peer Group: (Consolidated)					
Apollo Hospitals Enterprises Limited		147408.00	Not Available	Not Available	
Fortis Healthcare Limited		57449.48	Not Available	Not Available	
Max Healthcare Insitute Limited		40588.20	Not Available	Not Available	
Narayana Hrudayalaya Limited		37358.76	Not Available	Not Available	
Industry Avg:		70701.11	N.A.	N.A.	N.A.
Price to Earnings Ratio (P/E)		Issuer:			
		Consolidated (Diluted)	43.24	Not Available	Not Available
	Peer Group: (Consolidated)				
	Apollo Hospitals Enterprises Limited	59.44	Not Available	Not Available	
	Fortis Healthcare Limited	39.11	Not Available	Not Available	
	Max Healthcare Insitute Limited	73.24	Not Available	Not Available	
	Narayana Hrudayalaya Limited	43.82	Not Available	Not Available	
	Industry Avg:	53.90	N.A.	N.A.	N.A.
	RoNW(%)	Issuer:			
		Consolidated	12.14	Not Available	Not Available
Peer Group: (Consolidated)					
Apollo Hospitals Enterprises Limited		18.86	Not Available	Not Available	
Fortis Healthcare Limited		11.27	Not Available	Not Available	
Max Healthcare Insitute Limited		9.63	Not Available	Not Available	
Narayana Hrudayalaya Limited		22.97	Not Available	Not Available	
Industry Avg:		15.68	N.A.	N.A.	N.A.

NAV per Equity Share	Issuer:				
	Consolidated	63.82	Not Available	Not Available	Not Available
	Peer Group: (Consolidated)				
	Apollo Hospitals Enterprises Limited	408.78	Not Available	Not Available	Not Available
	Fortis Healthcare Limited	92.83	Not Available	Not Available	Not Available
	Max Healthcare Insitute Limited	64.79	Not Available	Not Available	Not Available
	Narayana Hrudayalaya Limited	72.88	Not Available	Not Available	Not Available
	Industry Avg:	159.82	N.A.	N.A.	N.A.

Notes:

(1) Sourced from Prospectus dated November 09, 2022.

(2) Information not provided as the relevant fiscal year has not completed

Key ratios for the Company for the three fiscal years stated above shall be calculated as follows:

(i) Basic Earnings per Share (Rs.) = net profit after tax and adjustments, attributable to equity shareholders / Weighted average no. of equity shares outstanding during the fiscal year.

Earnings per share calculations are in accordance with the notified Ind AS 33 'Earnings per share' notified accounting standard by the Companies (Indian Accounting Standards) Rules of 2015 (as amended).

(ii) Diluted Earnings per Share (Rs.) = net profit after tax and adjustments, attributable for equity shareholders (after adjusting profit impact of dilutive potential equity shares, if any) / the aggregate of weighted average number of Equity shares outstanding during the year and the weighted average number of Equity shares that would be issued on conversion of all the dilutive potential Equity shares into Equity shares.

(iii) Total Income = Revenue from Operations and Other Income

(iv) P/E (Basic/Diluted) - Closing Market Price at the end of relevant fiscal year end on NSE/ Basic/Diluted EPS

(v) Return on Net Worth (%) = Net profit after tax, available for equity shareholders / Net worth at the end of the fiscal year.

(vi) Net Asset Value per Equity Share = Net worth at the end of the fiscal year./ Number of equity shares outstanding as at the end of fiscal year

14 Any other material information

Date of disclosure	Announcement
16-Nov-22	Listing of equity shares of Electronics Mart India Ltd
17-Nov-22	Submission of Details Of Key Managerial Personnel Under Regulation 30(5) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 Of Global Health Limited ("The Company")
17-Nov-22	Submission of Code Of Practices And Procedures For Fair Disclosure Of Unpublished Price Sensitive Information

Source: Filings with BSE

Note: The Company meets Investors/ Analysts/ Participants from time to time. Please refer to the website of the Stock Exchanges for the intimation of the schedule of such meetings and related details, as applicable.

For further updates and information, please refer to the website of the Stock Exchanges i.e. www.bseindia.com and / or www.nseindia.com.

Disclaimer:

The information compiled herein is in accordance with the disclosure requirements with regard to the track record of the public issues managed by JM Financial Limited ("JM Financial") arising out of the SEBI Circular No. CIR/MIRSD/1/2012 dated January 10, 2012.

This information is gathered, inter-alia, from the Prospectus of the Issuer, as amended, and from the filings made by the Issuer with the BSE Limited ("BSE") and / or the National Stock Exchange of India Limited ("NSE" and together with the BSE, the "Stock Exchanges") from time to time, price-volume data available on the website of the Stock Exchanges, other sources as disclosed herein and information / clarifications provided by the Issuer.

Nothing in this information is intended by JM Financial to be construed as legal, regulatory, accounting, tax or other advice. While reasonable care has been taken to ensure that the information provided herein is accurate and is taken from the sources that we believe are reliable, the user of this information may independently verify the accuracy of the information before taking any decision based on the above information.

Notwithstanding the above, JM Financial does not make any express or implied representation or warranty as to the authenticity, accuracy or completeness of the information or data contained herein and shall not be liable in any manner for the same. Neither JM Financial nor any of its affiliates or their directors, officers and employees will be responsible or be liable for any loss or damage including any loss of profits incidental or consequential damage, howsoever arising, suffered or incurred by any person accessing and / or using this information. The person accessing and utilizing the information is accordingly once again advised to independently verify the information and satisfy himself about the adequacy, accuracy and completeness for his specific requirement. JM Financial does not undertake to update the information contained herein except as required by applicable law or regulation.